DIAGNOS Inc. provides software-based interpretation services primarily in Canada, the United States, Kenya, the United Arab Emirates, Bangladesh, Saudi Arabia, and Costa Rica. More Details
+ 2 more risks
Adequate balance sheet with weak fundamentals.
Share Price & News
How has DIAGNOS's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ADK's share price has been volatile over the past 3 months.
7 Day Return
CA Healthcare Services
1 Year Return
CA Healthcare Services
Return vs Industry: ADK exceeded the Canadian Healthcare Services industry which returned 34% over the past year.
Return vs Market: ADK exceeded the Canadian Market which returned -4.2% over the past year.
Price Volatility Vs. Market
How volatile is DIAGNOS's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StHow Is DIAGNOS' (CVE:ADK) CEO Compensated?
4 months ago | Simply Wall StWhat Kind Of Shareholder Appears On The DIAGNOS Inc.'s (CVE:ADK) Shareholder Register?
5 months ago | Simply Wall StShould You Worry About DIAGNOS Inc.'s (CVE:ADK) CEO Salary Level?
Is DIAGNOS undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ADK's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ADK's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ADK is unprofitable, so we can't compare its PE Ratio to the XN Healthcare Services industry average.
PE vs Market: ADK is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ADK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ADK is overvalued based on its PB Ratio (25.5x) compared to the CA Healthcare Services industry average (2.6x).
How is DIAGNOS forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as DIAGNOS has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine DIAGNOS's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- DIAGNOS competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has DIAGNOS performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ADK is currently unprofitable.
Growing Profit Margin: ADK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ADK is unprofitable, and losses have increased over the past 5 years at a rate of 3.5% per year.
Accelerating Growth: Unable to compare ADK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-4.8%).
Return on Equity
High ROE: ADK has a negative Return on Equity (-213.1%), as it is currently unprofitable.
How is DIAGNOS's financial position?
Financial Position Analysis
Short Term Liabilities: ADK's short term assets (CA$1.9M) exceed its short term liabilities (CA$530.6K).
Long Term Liabilities: ADK's short term assets (CA$1.9M) exceed its long term liabilities (CA$70.9K).
Debt to Equity History and Analysis
Debt Level: ADK's debt to equity ratio (23.1%) is considered satisfactory.
Reducing Debt: ADK had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADK has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ADK has less than a year of cash runway if free cash flow continues to reduce at historical rates of 0.9% each year
What is DIAGNOS current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ADK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ADK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ADK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ADK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ADK's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Andre Larente has been the Chief Executive Officer and President of Diagnos Inc. since June 22, 2004. Mr. Larente served as an Independent Director at Windfall Geotek Inc. (Formerly, Albert Mining Inc. ...
CEO Compensation Analysis
Compensation vs Market: Andre's total compensation ($USD226.32K) is above average for companies of similar size in the Canadian market ($USD171.43K).
Compensation vs Earnings: Andre's compensation has increased whilst the company is unprofitable.
|CEO, President & Executive Director||16.33yrs||CA$297.21k||0.38% |
|Independent Director||0.92yr||CA$54.40k||0.91% |
|Director||0.083yr||no data||0.21% |
|Director||0.083yr||no data||1.84% |
|Member of the Scientific Advisory Board||11.17yrs||no data||no data|
|Member of the Scientific Advisory Board||11.08yrs||no data||no data|
|Independent Director||2.5yrs||CA$23.68k||no data|
Experienced Board: ADK's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ADK insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.7%.
DIAGNOS Inc.'s company bio, employee growth, exchange listings and data sources
- Name: DIAGNOS Inc.
- Ticker: ADK
- Exchange: TSXV
- Founded: 1998
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: CA$34.365m
- Shares outstanding: 61.37m
- Website: https://www.diagnos.ca
- DIAGNOS Inc.
- 7005 Taschereau Boulevard
- Suite 340
- J4Z 1A7
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ADK||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||Nov 2000|
|4D4A||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Nov 2000|
|DGNO.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Nov 2000|
DIAGNOS Inc. provides software-based interpretation services primarily in Canada, the United States, Kenya, the United Arab Emirates, Bangladesh, Saudi Arabia, and Costa Rica. It offers image analysis serv ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/22 01:13|
|End of Day Share Price||2020/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.